• CG Oncology has reported first-quarter 2026 results, with revenue rising to US$1.08 million while net loss widened to US$60.20 million, and is preparing to share initial Phase 2 CORE-008 data on its intravesical combination therapy for high-risk non-muscle invasive bladder cancer at the AUA 2026 Annual Meeting.
• The upcoming CORE-008 presentations, alongside fellowship-backed research on tumor microenvironment and heterogeneity in BCG-unresponsive disease, underscore CG Oncology’s focus on advancing gene-based bladder cancer treatments and scientific credibility within the urology community.
• We’ll now consider how the forthcoming CORE-008 Phase 2 data release may influence CG Oncology’s investment narrative amid recent share price weakness.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

What Is CG Oncology's Investment Narrative?

For CG Oncology, the big picture an investor needs to buy into is a high-risk, high-science story around cretostimogene grenadenorepvec as a gene-based backbone for non muscle invasive bladder cancer. The core near term catalysts still sit with the Phase 3 programs, particularly the expedited PIVOT-006 topline readout and continued BOND-003 follow up, but the new CORE-008 Phase 2 data at AUA could now act as an incremental sentiment driver rather than a primary share price mover. With the stock up strongly over the past year yet soft in the last week, the AUA presentations and research fellowships mainly reinforce CG Oncology’s scientific positioning rather than change the commercial outlook, while the widening quarterly net loss underlines that ongoing cash burn and future funding needs remain front and center.

However, CG Oncology’s growing losses and potential future funding requirements are information investors should be aware of. Despite retreating, CG Oncology's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

With one very large US$351.97 fair value estimate from the Simply Wall St Community, you are seeing just one retail view on CG Oncology. Set that against the upcoming Phase 3 readouts and persistent losses, and it is clear why many market participants may be weighing very different outcomes for the business.

Explore another fair value estimate on CG Oncology - why the stock might be worth over 5x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your CG Oncology research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free CG Oncology research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CG Oncology's overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.